InspireMD (NYSE:NSPR) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR) in a research note issued to investors on Wednesday. The brokerage set a “sell” rating on the stock.

Separately, Lake Street Capital began coverage on InspireMD in a research note on Wednesday, December 11th. They issued a “buy” rating and a $5.00 target price on the stock.

InspireMD Stock Up 0.7 %

NYSE NSPR opened at $2.70 on Wednesday. The firm has a market cap of $80.16 million, a P/E ratio of -3.60 and a beta of 0.88. InspireMD has a 52-week low of $1.81 and a 52-week high of $3.80. The business’s 50-day moving average price is $2.86 and its 200 day moving average price is $2.76.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Parkman Healthcare Partners LLC boosted its holdings in InspireMD by 721.2% in the 4th quarter. Parkman Healthcare Partners LLC now owns 854,716 shares of the company’s stock valued at $2,248,000 after purchasing an additional 750,635 shares in the last quarter. Schonfeld Strategic Advisors LLC lifted its holdings in shares of InspireMD by 153.2% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 30,133 shares of the company’s stock valued at $79,000 after buying an additional 18,233 shares during the period. Northern Trust Corp boosted its stake in shares of InspireMD by 103.7% in the fourth quarter. Northern Trust Corp now owns 48,022 shares of the company’s stock valued at $126,000 after buying an additional 24,452 shares in the last quarter. Renaissance Technologies LLC acquired a new position in InspireMD during the fourth quarter worth $27,000. Finally, Essex Investment Management Co. LLC acquired a new position in InspireMD during the fourth quarter worth $191,000. 44.78% of the stock is currently owned by institutional investors and hedge funds.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.